Novartis Reports Better-Than-Expected Q2 Sales Amid Upcoming Patent Challenges
Novartis reported a better-than-expected second-quarter sales increase of $14.4 billion, driven by strong performance from newer products like Kisqali and Kesimpta. Despite declining revenue for Entresto due to generic competition, the company remains optimistic about its pipeline ahead of several patent expirations over the next five years.
Tickers: $NVS
Topics: drug sales earnings report patent cliff pharmaceuticals